Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Maeda

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
International Immunology|August 23, 2022
The proliferative activity levels of each immune cell population evaluated by mass cytometry are linked to the clinical phenotypes of systemic lupus erythematosusAkiko Kajihara, Takayoshi Morita, Yasuhiro Kato, et al.
Frontiers in Microbiology|March 7, 2017
Fungal ITS1 Deep-Sequencing Strategies to Reconstruct the Composition of a 26-Species Community and Evaluation of the Gut Mycobiota of Healthy Japanese IndividualsDaisuke Motooka, Kosuke Fujimoto, Reiko Tanaka, et al.
Frontiers in Cellular and Infection Microbiology|December 28, 2020
A Metagenome-Wide Association Study of Gut Microbiome in Patients With Multiple Sclerosis Revealed Novel Disease PathologyToshihiro Kishikawa, Kotaro Ogawa, Daisuke Motooka, et al.
Rheumatology International|July 31, 2020
Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort studySadao Jinno, Akira Onishi, Maureen Dubreuil, et al.
Clinical Rheumatology|March 13, 2020
Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Arthritis Research & Therapy|June 17, 2020
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Arthritis Research & Therapy|May 8, 2019
Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Modern Rheumatology Case Reports|October 22, 2020
Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature reviewYuta Yamaguchi, Yuichi Maeda, Takayuki Shibahara, et al.
Rheumatology International|October 18, 2019
The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort studyKoichi Murata, Motomu Hashimoto, Wataru Yamamoto, et al.
Arthritis Research & Therapy|April 12, 2019
Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
International Immunology|August 23, 2022
The proliferative activity levels of each immune cell population evaluated by mass cytometry are linked to the clinical phenotypes of systemic lupus erythematosusAkiko Kajihara, Takayoshi Morita, Yasuhiro Kato, et al.
Frontiers in Microbiology|March 7, 2017
Fungal ITS1 Deep-Sequencing Strategies to Reconstruct the Composition of a 26-Species Community and Evaluation of the Gut Mycobiota of Healthy Japanese IndividualsDaisuke Motooka, Kosuke Fujimoto, Reiko Tanaka, et al.
Frontiers in Cellular and Infection Microbiology|December 28, 2020
A Metagenome-Wide Association Study of Gut Microbiome in Patients With Multiple Sclerosis Revealed Novel Disease PathologyToshihiro Kishikawa, Kotaro Ogawa, Daisuke Motooka, et al.
Rheumatology International|July 31, 2020
Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort studySadao Jinno, Akira Onishi, Maureen Dubreuil, et al.
Clinical Rheumatology|March 13, 2020
Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Arthritis Research & Therapy|June 17, 2020
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Arthritis Research & Therapy|May 8, 2019
Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Modern Rheumatology Case Reports|October 22, 2020
Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature reviewYuta Yamaguchi, Yuichi Maeda, Takayuki Shibahara, et al.
Rheumatology International|October 18, 2019
The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort studyKoichi Murata, Motomu Hashimoto, Wataru Yamamoto, et al.
Arthritis Research & Therapy|April 12, 2019
Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Pageof 8